References
- Lain SJ, Roberts CL, Bowen JR, et al. Trends in New South Wales infant hospital readmission rates in the first year of life: a population-based study. Med J Aust 2014;201:40–3.
- The Young Infants Clinical Signs Study Group. Clinical signs that predict severe illness in children under age 2 months: a multicentre study. Lancet 2008;371:135–42.
- Tomashek KM, Crouse CJ, Iyasu S, et al. A comparison of morbidity rates attributable to conditions originating in the perinatal period among newborns discharged from United States hospitals, 1989–90 and 1999–2000. Paediatr Perinat Epidemiol 2006;20:24–34.
- American Academy of Pediatrics (AAP). Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297–6.
- National Institute for Health and Clinical Excellence (NICE), UK. Neonatal jaundice (Clinical guideline 98); 2010. Available from: www.nice.org.uk/CG98 [last accessed 30 Oct 2016].
- Olusanya BO, Ogunlesi TA, Kumar P, et al. Management of late-preterm and term infants with hyperbilirubinaemia in resource-constrained settings. BMC Pediatrics 2015;15:39.
- Steiner LA, Bizzarro MJ, Ehrenkranz RA, et al. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics 2007;120:27–32.
- Volpe JJ, Bilirubin and brain injury. In: Volpe JJ, ed. Neurology of the newborn. 5th ed. Philadelphia (PA): WB Saunders; Elsevier Inc.; 2008:619–46.
- Lunsing RJ. Subtle bilirubin-induced neurodevelopmental dysfunction (BIND) in the term and late preterm infant: does it exist? Semin Perinatol 2014;38:465–71.
- Johnson L, Brown AK, Bhutani VK. BIND: a clinical score for bilirubin induced dysfunction in newborns. Pediatrics 1999;104:746–7.
- Bao Y, Chen XY, Shi LP, et al. Clinical features of 116 near term and term infants with acute bilirubin encephalopathy in Eastern China. HK J Paediatr (New Series) 2013;18:82–8.
- Gamaleldin R, Iskander I, Seoud I, et al. Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia. Pediatrics 2011;128:e925–31.
- Radmacher PG, Groves FD, Owa JA, et al. A modified Bilirubin-induced neurologic dysfunction (BIND-M) algorithm is useful in evaluating severity of jaundice in a resource-limited setting. BMC Pediatrics 2015;15:28.
- Dubowitz LM, Mercuri E, Dubowitz V. An optimality score for the neurologic examination of the term newborn. J Pediatr 1998;133:406–16.
- McGready R, Simpson J, Panyavudhikrai S, et al. Neonatal neurological testing in resource-poor settings. Ann Trop Paediatr 2000;20:323–36.
- Olusanya BO, Ogunlesi TA, Slusher TM. Why is kernicterus still a major cause of death and disability in low-income and middle-income countries? Arch Dis Child 2014;99:1117–21.
- Olusanya BO, Emokpae AA, Zamora TG, et al. Addressing the burden of neonatal hyperbilirubinaemia in countries with significant glucose-6-phosphate dehydrogenase deficiency. Acta Paediatr 2014;103:1102–9.
- Bratlid D, Nakstad B, Hansen TW. National guidelines for treatment of jaundice in the newborn. Acta Paediatr 2011;100:499–505.
- Khassawneh M, Rubaie Z, Khashashneh I, et al. Adherence with American Academy of Pediatrics guidelines when managing neonatal jaundice in Jordan. Res Rep Neonatol 2013;3:27–31.
- Ogunlesi TA, Ogunfowora OB. Predictors of acute bilirubin encephalopathy among Nigerian term babies with moderate-to-severe hyperbilirubinaemia. J Trop Pediatr 2011;57:80–6.
- Arnolda G, Nwe HM, Trevisanuto D, et al. Risk factors for acute bilirubin encephalopathy on admission to two Myanmar national paediatric hospitals. Matern Health Neonatol Perinatol 2015;1:22.
- Beutler E, Blume K, Kaplan J, et al. International Committee for Standardization in Haematology: recommended screening test for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Br J Haematol 1979;3:465–7.
- Hulzebos CV, Dijk PH. Bilirubin-albumin binding, bilirubin/albumin ratios, and free bilirubin levels: where do we stand? Semin Perinatol 2014;38:412–21.
- Olusanya BO, Iskander IF, Slusher TM, et al. A decision-making tool for exchange transfusions in infants with severe hyperbilirubinemia in resource-limited settings. J Perinatol 2016;36:338–41.
- Mukhopadhyay K, Chowdhary G, Sing P, et al. Neurodevelopmental outcome of acute bilirubin encephalopathy. J Trop Pediatr 2010;56:333–6.
- Wolf MJ, Beunen G, Casaer P, et al. Neurological status in severely jaundiced Zimbabwean neonates. J Trop Pediatr 1998;44:161–4.
- Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics 1997;9:E7.
- Mabogunje CA, Olaifa SM, Olusanya BO. Facility-based constraints to exchange transfusions for neonatal hyperbilirubinemia in resource-limited settings. World J Clin Pediatr 2016;5:182–90.
- Sherbiny HS, Youssef DM, Sherbini AS, et al. High-intensity light-emitting diode vs fluorescent tubes for intensive phototherapy in neonates. Paediatr Int Child Health 2016;36:127–33.
- Mateo PC, Lee KS, Barozzino M, et al. Management of neonatal jaundice varies by practitioner type. Can Fam Phys 2013;59:e379–86.